Kadimastem Ltd. and NLS Pharmaceutics Announce Binding Term Sheet to Merge
The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical...
top of page
Not compatible with Internet Explorer
Not compatible with Internet Explorer
Not compatible with Internet Explorer
Search
- Jun 23
- 5 min
The World Prestigious Diabetes Research Institute, University of Miami, Announces Kadimastem's Joint Project as Breakthrough Transplantation Approach for the Treatment of Type 1 Diabetes
The results were presented at the 84th scientific conference of the American Diabetes Association (ADA) Kadimastem Ltd. (TASE: KDST),...
- Feb 28
- 3 min
Kadimastem Takes Another Step Towards Signing the Merger Agreement with Nasdaq Listed IMCC
Kadimastem reveals that the company with which it has signed a non-binding memorandum of understanding for a merger is IMCC (NASDAQ:...
- Feb 15
- 3 min
Kadimastem advances towards Nasdaq: Company Signs a Memorandum of Understanding to Merge with a Company traded on the Nasdaq
Kadimastem shareholders to hold 88% of the shares of the combined company post-merger Kadimastem Ltd. (TASE: KDST), a leading cell...
- Feb 7
- 4 min
Kadimastem Receives Patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes in India
The patent approval in India strengthens the company’s global position in the diabetes field Ness Ziona, Israel, February 7th, 2024 ,...
- Jan 25
- 3 min
A peer reviewed article on Kadimastem's AstroRx® Cryopreserved off the Shelf Cell Product for the Treatment of ALS was Published in the Journal of Clinical Toxicology
The publication presents the development and preclinical safety of Kadimastem's off the shelf AstroRx ("thaw to inject") cell product in...
- Jan 22
- 4 min
Kadimastem and iTolerance Complete Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting with the U.S. FDA
Companies Advancing Joint Clinical Development of a Potential Cure for Diabetes Without the Need for Chronic Suppression of the Immune...
- Nov 7, 2023
- 4 min
Kadimastem and iTolerance Submit INTERACT Request with FDA for Potential Cure for Type 1 Diabetes
Kadimastem and iTolerance signed a collaboration agreement several months ago to co-develop cell technology as a potential cure for...
- Jun 20, 2023
- 4 min
Kadimastem Receives US Patent for Its Cell Selection & Enrichment Technology Used to Develop IsletRx
The patent approval in the US strengthens the company’s global leadership position in the diabetes field Ness Ziona, Israel, June 20th,...
- May 15, 2023
- 3 min
Kadimastem Granted European Patent for Its IsletRx Treatment for Diabetes
Kadimastem Granted European Patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes...
- May 9, 2023
- 5 min
Kadimastem and iTolerance Sign Agreement and Receive US$1 Million from BIRD Foundation
The grant is intended for the joint development of a potential cure for diabetes without the need for chronic suppression of the immune...
- Mar 19, 2023
- 4 min
Kadimastem Earns FDA IND Approval For its US Phase IIa Clinical Trial with AstroRx® to Treat ALS
IND Approval Allows Commencement of the Multi-Site Clinical Trial and Recruitment of Eligible ALS Patients for Repeated Dosing of...
- Feb 19, 2023
- 5 min
Kadimastem Submits IND Application to the FDA for its Phase IIa Clinical Trial with AstroRx® for ALS
The study will Determine if Repeated Dosing of AstroRx® in Three-month Intervals Achieves a Continuous Delay of the Progression of ALS to...
- Feb 15, 2023
- 4 min
Kadimastem's Clinical Trial in ALS Patients was Publicized in the Journal of Translational Medicine
The publication presents the company’s successful phase I/IIa clinical trial in Israel to evaluate the safety, tolerability, and...
- Feb 5, 2023
- 4 min
Awarded Patent in Australia for its AstroRx® Technology for the Treatment of ALS and Drug Screening
It’s in addition to the company's patents for the product in the US, Europe, Japan and Israel. The patent grant strengthens the company's...
- Jan 9, 2023
- 3 min
Kadimastem Announces it raised appx 7.5 million NIS by rights offering
The company's main stakeholders, Prof. Michel Revel and Mr. Julian Ruggeri and the European Alpha Capital Anstalt, expressed confidence...
- Dec 20, 2022
- 5 min
Kadimastem and iTolerance’s Proposed Collaboration With Receipt of US $1 Million BIRD Grant
Kadimastem and iTolerance’s Proposed Collaboration to Develop a Potential Cure for Diabetes is Further Strengthened With Receipt of NIS...
- Sep 28, 2022
- 4 min
Kadimastem Receives Approval of Patent registration Used to Develop IsletRx for Diabetes
Cell Selection and Enrichment Technology is Used to Develop IsletRx Treatment for Diabetes in a Third Territory This approval of...
- Aug 9, 2022
- 4 min
Kadimastem Receives US Patent For Amyotrophic Lateral Sclerosis (ALS) Treatment
The patent supports the Phase IIa study of AstroRx® for ALS planned to begin in the US in 2023 Ness Ziona, Israel, August 9, 2022 ---...
- Jun 8, 2022
- 4 min
Kadimastem and Implant Therapeutics, Inc. Sign an Evaluation Agreement
The Evaluation Agreement is Towards the Potential Licensing of “Immune Evasive” Cells If the feasibility study is successful, it would be...
bottom of page